Literature DB >> 24733991

CPAP therapy reverses weakness of myasthenia gravis: role of obstructive sleep apnea in paradoxical weakness of myasthenia gravis.

Ki-Hwan Ji1, Jong Seok Bae2.   

Abstract

Fatigability after exercise and restoration of strength by rest are clinical hallmarks of myasthenia gravis (MG). These unique features are originated from a reduced safety factor, which is related to a defect of acetylcholine receptor, and post-exercise exhaustion of neuromuscular junction transmission. Therefore, most patients with MG feel recharged muscle strength and show normal muscle power after nocturnal sleep. As such, worsening of MG symptoms during nighttime is usual. However, in very rare cases, some patients with MG complain fatigability and weakness in the morning, so called "paradoxical weakness (PW)." We report two MG patients with typical PW, diagnosed with OSA by polysomnography. CPAP therapy successfully improved their morning symptoms and quality of life. So far, the detailed mechanism of PW in MG is unknown; however, our report highlights the possible role of sleep disorders in developing a PW in MG and the therapeutic target for life quality of MG.

Entities:  

Keywords:  CPAP; Myasthenia gravis; obstructive sleep apnea; paradoxical weakness

Mesh:

Year:  2014        PMID: 24733991      PMCID: PMC3960388          DOI: 10.5664/jcsm.3626

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  8 in total

Review 1.  Safety factor at the neuromuscular junction.

Authors:  S J Wood; C R Slater
Journal:  Prog Neurobiol       Date:  2001-07       Impact factor: 11.685

Review 2.  Epidemiology of obstructive sleep apnea: a population health perspective.

Authors:  Terry Young; Paul E Peppard; Daniel J Gottlieb
Journal:  Am J Respir Crit Care Med       Date:  2002-05-01       Impact factor: 21.405

Review 3.  Effects of sleep and circadian rhythm on the human immune system.

Authors:  Tanja Lange; Stoyan Dimitrov; Jan Born
Journal:  Ann N Y Acad Sci       Date:  2010-04       Impact factor: 5.691

4.  Sleep apnea in patients with myasthenia gravis.

Authors:  M W Nicolle; S Rask; W J Koopman; C F P George; J Adams; S Wiebe
Journal:  Neurology       Date:  2006-07-11       Impact factor: 9.910

5.  Long-term sleep apnea as a pathogenic factor for cell-mediated autoimmune disease.

Authors:  Burton Abrams
Journal:  Med Hypotheses       Date:  2005-08-05       Impact factor: 1.538

Review 6.  Myasthenia gravis.

Authors:  D B Drachman
Journal:  N Engl J Med       Date:  1994-06-23       Impact factor: 91.245

Review 7.  Interactions between obesity and obstructive sleep apnea: implications for treatment.

Authors:  Abel Romero-Corral; Sean M Caples; Francisco Lopez-Jimenez; Virend K Somers
Journal:  Chest       Date:  2010-03       Impact factor: 9.410

8.  Improvement in ocular myasthenia gravis during CPAP therapy for sleep apnea.

Authors:  Saira Naseer; Victor O Kolade; Sarim Idrees; Sidra Naseer; Anuj Chandra
Journal:  Tenn Med       Date:  2012-10
  8 in total
  1 in total

1.  Sleep Disordered Breathing Mimicking Myasthenia Crisis in a Patient with Myasthenia Gravis.

Authors:  Yi-Chun Lai; Jung-Yueh Chen; Huey-Dong Wu; Chih-Chao Yang; Chin-Hsien Lin; Pei-Lin Lee
Journal:  J Clin Sleep Med       Date:  2016-05-15       Impact factor: 4.062

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.